CJC-1295 vs Ipamorelin: GHRH Analog vs Ghrelin-Pathway Research
A research-first comparison of two GH-axis peptides: what each component does, why researchers pair them, and where the evidence stops short of direct commercial-blend claims.
CJC-1295 vs Ipamorelin at a Glance
| Research factor | CJC-1295 | Ipamorelin |
|---|---|---|
| Signal family | GHRH analog | Ghrelin-receptor / GH-secretagogue pathway |
| Published timing profile | Longer duration; GH and IGF-1 signal measured over days in adult volunteer research[2] | Shorter profile; human PK/PD work describes a single GH release episode[5] |
| Mechanistic anchor | Albumin-binding hGRF(1-29) analog design[1] | Selective GH secretagogue pharmacology[4] |
| Evidence gap | A direct, mature peer-reviewed evidence base for the marketed CJC-1295 plus ipamorelin blend remains thinner than the component evidence. | |
What Is CJC-1295?
CJC-1295 is a long-acting analog of growth hormone-releasing hormone. Jette et al. identified CJC-1295 while developing hGRF(1-29)-albumin bioconjugates that activate the GRF receptor and extend exposure compared with shorter parent analogs.[1]
In healthy adult research, Teichman et al. reported dose-dependent increases in mean plasma GH concentrations for six days or more and IGF-1 concentrations for 9 to 11 days after a single CJC-1295 administration. The same paper estimated a half-life of about 5.8 to 8.1 days.[2]
A separate study by Ionescu and Frohman reported that pulsatile GH secretion persisted during continuous stimulation by CJC-1295. That nuance matters: the compound extends GHRH-type stimulation, but the cited work did not describe a simple flat output stream.[3]
What Is Ipamorelin?
Ipamorelin is usually discussed as a selective GH secretagogue rather than a GHRH analog. Raun et al. described it as the first selective growth-hormone secretagogue and characterized its GH-releasing activity in preclinical pharmacology systems.[4]
The useful contrast is timing. Gobburu et al. reported that ipamorelin had a short terminal half-life of about 2 hours in healthy male volunteers and produced a single GH release episode with peak GH response at about 0.67 hours.[5]
That shorter profile is why ipamorelin is often placed on the "pulse" side of the research comparison, while CJC-1295 sits on the longer GHRH-signaling side.
Why Are They Paired in Research?
The pairing has a coherent pathway rationale: one peptide sits on the GHRH side and the other on the ghrelin-family GH-secretagogue side. Arvat et al. showed that ghrelin plus GHRH produced synergistic GH release in human physiology research, larger than either signal alone.[6]
That source is important, but it should be interpreted carefully. Arvat et al. studied ghrelin and GHRH physiology, not a commercial CJC-1295 plus ipamorelin vial. The paper supports the concept of complementary signaling; it does not validate every blend claim made online.
Where the Evidence Stops
The strongest evidence base is component-specific: CJC-1295 alone, ipamorelin alone, and pathway-level GH-axis synergy. For a research-use supplier, the conservative framing is to describe the blend as a component-backed research format, not as a finished product with mature direct outcome evidence.
For broader context, see the CJC-1295 + Ipamorelin blend guide, the GHRH peptides comparison, the peptide stability guide, and the bacteriostatic water guide. Product-format details sit separately at CJC-1295 + Ipamorelin 5mg + 5mg.
Where Tesamorelin Fits the CJC-1295 vs Ipamorelin Picture
A common follow-up is how tesamorelin compares with this pairing. The key point is that tesamorelin lands on the same side of the GH axis as CJC-1295, not ipamorelin: Wang and Tomlinson described tesamorelin as a synthetic human growth hormone-releasing factor (GHRH/GRF) analogue.[7]
That places tesamorelin and CJC-1295 together in the GHRH-analog family, both acting on the GHRH-receptor side of the GH axis, while ipamorelin remains the ghrelin-receptor secretagogue. A tesamorelin-versus-ipamorelin comparison therefore maps onto the same GHRH-versus-ghrelin contrast as CJC-1295 versus ipamorelin, just with a different GHRH-side molecule. The molecules are not interchangeable: tesamorelin and CJC-1295 are distinct analogs with different sequences and published profiles.
This is also why a tesamorelin–ipamorelin stack is discussed in the same breath as the CJC-1295 plus ipamorelin pairing. Both combine a GHRH-side signal with a ghrelin-side secretagogue, so they share the same pathway rationale and the same caveat: pathway-level plausibility is documented, but a mature direct outcome base for any specific marketed blend stays thinner than the single-component literature. For research-use context, that means treating either blend concept as a component-backed research format rather than a separately validated entity.
Our Research Standards
This article uses peer-reviewed endocrine pharmacology and human GH-axis physiology literature. Product references are limited to research-use format and verification context. Read our editorial policy →
CJC-1295 vs Ipamorelin FAQ
What is the simplest difference between CJC-1295 and ipamorelin?
CJC-1295 is a long-acting GHRH analog. Ipamorelin is a selective GH secretagogue linked to ghrelin-receptor signaling. They sit on different sides of GH-axis research.
Which has the longer published duration?
CJC-1295. The Teichman study reported GH elevation for six days or more and IGF-1 elevation for 9 to 11 days after a single administration in healthy adult research.[2]
Does the blend have the same evidence strength as the components?
No. The component and pathway evidence is stronger than the direct published evidence for marketed CJC-1295 plus ipamorelin blend formats.
Is this article a human-use protocol?
No. It is a literature comparison for in-vitro laboratory research context only. Remy Peptides products are not for human or veterinary use.
What is the difference between tesamorelin and ipamorelin?
Tesamorelin and ipamorelin sit on opposite sides of the GH axis. Tesamorelin is a growth hormone-releasing factor (GHRH/GRF) analogue, putting it in the same family as CJC-1295, while ipamorelin is a selective ghrelin-receptor secretagogue. The contrast therefore mirrors the CJC-1295 versus ipamorelin one: a GHRH-side molecule versus a ghrelin-side molecule.[7]
Where can I buy CJC-1295 and ipamorelin?
That is a purchasing question rather than a research one, so this comparison does not cover it. Any product-format and availability details, where offered, sit on the relevant product page; this article only covers the CJC-1295 versus ipamorelin research literature for in-vitro laboratory research context.
- Jette L, Leger R, Thibaudeau K, et al. Human growth hormone-releasing factor hGRF(1-29)-albumin bioconjugates; identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005. DOI: 10.1210/en.2004-1286.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged GH and IGF-1 stimulation by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006. PubMed: 16352683.
- Ionescu M, Frohman LA. Pulsatile secretion of GH persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab. 2006. DOI: 10.1210/jc.2006-1702.
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998. PubMed: 9849822.
- Gobburu JVS, Agersoe H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin. Pharmaceutical Research. 1999. PubMed: 10554061.
- Arvat E, Di Vito L, Broglio F, et al. Ghrelin endocrine activity and interactions with GHRH in humans. J Clin Endocrinol Metab. 2001. DOI: 10.1210/jcem.86.3.7312.
- Wang Y, Tomlinson B. Tesamorelin, a human growth hormone releasing factor analogue. Expert Opinion on Investigational Drugs. 2009. PubMed.